University of California

University of Louisville Research Foundation

Max Biopharma, Inc.

Farhad Parhami

Michael E Jung

Frank Stappenbeck

Khanhlinh Nguyen

Woo-Kyun Kim

William M Pierce, Jr

Dongwon Yoo

K Grant Taylor

Yi Chiao Fan

Brian T Chamberlain

Feng Wang

Kevyn Merten

Jennifer R Dwyer

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit Hedgehog signaling. Also described herein are methods for using such Hedgehog signaling inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of Hedgehog signaling.

Oxysterols and Hedgehog signaling

Oxysterol-bisphosphonate and oxysterol-alendronic acid compounds, compositions including them, and methods using them for the treatment of bone disorders.

Bone-selective osteogenic oxysterol bisphosphonate analogs

This invention relates, e.g., to a synthetic compound, Oxy133, having the structure [Formula I] or a bioactive or pharmaceutical composition comprising Oxy133 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders. 

Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis

Compounds and compositions for the treatment of bone disorders are presented.

Bone-selective osteogenic oxysterol-bone targeting agents

This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention.

Oxysterol compounds and the hedgehog pathway

The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and methods to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents, such as bone morphogenic proteins, known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders and implants to facilitate bone repair.

Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins

Synthetic oxysterols can be made and can be used for the treatment of bone disorders, obesity, cardiovascular disorders, and neurological disorders.

Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling

This invention relates to methods for using agents to inhibit peroxisome proliferator activated receptor expression.

Inhibition of PPAR gamma expression by specific osteogenic oxysterols

The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and method to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders, local injections of oxysterols or cells () and implants () having agents or cells () to facilitate bone repair.

Growing community of inventors

Los Angeles, CA, United States of America

Farhad Parhami